is rybelsus glp 1 Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes. #longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews #healthinnovation Everything You Need to Know

pharmacodynamic overlap possible via shared antioxidant pathways Primary concern / IV glutathione and liver-enzyme monitoring in patients on dulaglutide Monitoring recommended / LFTs at baseline and periodically when adding high-dose IV glutathione Evidence gap / no randomized controlled trial has tested the combination directly GLP-1 antioxidant effect / dulaglutide independently reduces oxidative stress markers in human studies Key guideline / ADA Standards of Care 2024 does not list glutathione as contraindicated with GLP-1 agents Bottom line / low-dose oral glutathione appears safe

Kein Einlass

Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials

And could they extend not just metabolic health, but also healthspanthe years lived in good health

Beyond these primary actions, palmatine also inhibits adipogenesis, as evidenced by its suppression of fat accumulation and downregulation of key adipogenic transcription factors PPAR- and C/EBP- in 3T3-L1 pre-adipocytes 21